RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Chengdu’s HitGen announced a drug discovery collaboration with Gilead Sciences to identify small molecule leads against targets specified by Gilead. HitGen will use its technology platform, based on DNA-encoded library design, synthesis and interrogation, to discover novel leads. HitGen believes its DNA encoded chemical libraries (DELs) contain 400 billion highly diverse, drug-like small molecules and macrocycles. HitGen will receive an undisclosed upfront payment and will be eligible for milestone payments from Gilead.
Source: China Biotoday
